ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2011
GSTM1 and GSTT1 copy number variation in population-based studies of endometrial cancer risk.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Structural and Functional Characterization ofLife (Basel, Switzerland) · 2022Article
- Up-regulation of GSTT1 in serous ovarian cancer associated with resistance to TAXOL / carboplatin.Journal of ovarian research · 2021Article
- Overexpression of <em>MYBL2</em> predicts poor prognosis and promotes oncogenesis in endometrial carcinoma.European journal of histochemistry : EJH · 2021Article
- Endometrial cancer: a genetic point of view.Translational cancer research · 2020Article
- Article
- GSTM1 and GSTT1 copy number variants and the risk to Thai females of hepatocellular carcinoma.Journal of gastrointestinal oncology · 2019Article
- Is There Any Association between Glutathione S-transferases M1 and Glutathione S-transferases T1 Gene Polymorphisms and Endometrial Cancer Risk? A Meta-analysis.International journal of preventive medicine · 2017Review
- Functional variants in CYP1A1 and GSTM1 are associated with clearance of cervical HPV infection.Gynecologic oncology · 2014Article
- A translational medicine appraisal of specialized andrology testing in unexplained male infertility.International urology and nephrology · 2014Review
- Worldwide population distribution of the common LCE3C-LCE3B deletion associated with psoriasis and other autoimmune disorders.BMC genomics · 2013Article
- GSTM1 and GSTT1 copy numbers and mRNA expression in lung cancer.Molecular carcinogenesis · 2012Article
- Challenges and opportunities in genome-wide environmental interaction (GWEI) studies.Human genetics · 2012Review
- Identification of germline genomic copy number variation in familial pancreatic cancer.Human genetics · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundGlutathione S-transferases (GST) detoxify a broad range of carcinogenic metabolites and lack of GSTM1 and GSTT1 activity due to gene deletions are prevalent. The associations of GSTM1 and GSTT1 polymorphisms with endometrial cancer risk have been inconsistent.
methodsWe investigated gene dosage effects of GSTM1 and GSTT1 copy number in 441 endometrial cancer cases and 1,237 matched controls selected from the Nurses' Health Study and Women's Health Study, as well as gene-environment interactions.
resultsCarriers of at least 2 GSTT1 genes had an increased risk of endometrial cancer (OR = 1.51, 95% CI = 1.04-2.19; P(trend) = 0.04) compared with women who were GSTT1 null. GSTM1 was not associated with endometrial cancer risk (OR(2/3 vs. 0 copies) = 0.82, 95% CI = 0.52-1.27; P(trend) = 0.41). We did not observe effect modification of either the GSTM1 or GSTT1 association with cancer risk by smoking status, postmenopausal hormone use, or body mass index.
conclusionsOur results suggested GSTM1 copy number does not influence endometrial cancer risk, whereas higher GSTT1 copy number may be associated with increased risk. Our findings supported that GSTT1 differs in its substrate specificity from GSTM1 and may generate intermediates more genotoxic to endometrial cells than the parent chemical. Future studies are needed to clarify this relationship. IMPACT: We hypothesized risk associated with GST enzymes may differ depending on environmental and/or occupational exposures. Our assessment of gene-environment interactions suggested GSTM1 and GSTT1 are not involved in the in vivo human metabolism of estrogen and its metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.